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Background
• CO2 present in Earth’s atmosphere at a partial pressure of 0.3 mmHg
• Historically unable to get to terrestrial levels with regenerable hardware
Lithium Hydroxide (LiOH) Canisters
• Permanent conversion from Li to Li2CO3
(single use)
• Each canister weighs 7 lbs
• Reserved for contingency use
• 20 canisters would provide 14 days 
of CO2 removal for 6 crew 
Carbon Dioxide Removal Assembly
• Regenerable system
• Zeolite desiccant-adsorbent beds
• Typically control ppCO2 to 2-5 mmHg
• Constrained by power, parts, crew time 
for maintenance
Brief History of CO2 Control Levels
• Shuttle and original ISS Flight Rule limit for CO2 was 7.6 mmHg 
• Based on existing terrestrial data 
• Consistent with recommendations set by OSHA and NIOSH in the 1980’s
• Throughout ISS program, anecdotal reports have suggested that 
crewmembers develop CO2-related symptoms at lower CO2 levels 
than would be expected terrestrially
• FR limit revised to 5.3 mmHg in 2008
• Based on new terrestrial data and the established Space Maximum Allowable 
Concentration (SMAC) for 7 to 180 days
• Since 2010, operational limits have been driven by crew 
symptomatology, and Chits have limited the 24-hour average CO2
to 4.0 mmHg or below. 
• Of note, OSHA and NIOSH have since adjusted their exposure limits to 3.8 
mmHg (8-hour TWA) and our interim SMAC value is set at 4.0 mmHg.
CO2 Symptoms in Spaceflight
• In spaceflight, symptoms seem to occur at lower 
CO2 levels than terrestrially
• Reported symptoms include:
• Fatigue
• Difficulty concentrating
• Irritability
• Performance decrements
• Headache
• One of the more easily recognized symptoms
• Clinically attributed to CO2 when symptoms are not attributed 
to another cause and symptoms resolve with lowering of CO2
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ppCO2 controlled to 5 mmHg
Conditional
ppCO2 controlled to 4 mmHg
Law, et al. Relationship Between CO2 Levels and Reported Headaches on the ISS, JOEM 2014
7CO2 Operational Control Levels:
Recent Experience
• We have operated to control limits less than 4 mmHg for portions 
of 4 out of 6 recent increments
• Range: 2.7 mmHg (3-hr avg) – 3.4 mmHg (24-hr avg)
• Reports from multiple crewmembers:
CO2 (mmHg) Observations
< 2.3 Few reports attributable to CO2
2.3 - 2.7 Fatigue, full-headedness
2.7 - 3.0 Self-reports of performance decrements, procedure missed 
steps, procedures going long 
> 3.0 Headaches (variable – between 3.0 and 3.4 mmHg) [in 
addition to the symptoms experienced at lower CO2]
Notes: Early, semi-quantitative data; range of inter- and intra-individual 
variability in sensitivity to CO2
Moving Target…
• Same crewmember
• One month into mission, denied any CO2 symptoms 
when CO2 peaked at 4.02 mmHg due to Node 3 
CDRA failure
• 2 months later, reported symptoms at 3.5-4 mmHg
• Two weeks prior, CO2 elevated due to
• Back-to-back SPHERES run and METOX regen
• Node 3 CDRA down
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Theories
Why do symptoms occur at lower CO2 levels in flight than 
terrestrially?
• Physiologic changes induced by microgravity result in 
changes to CO2 sensitivity
• Localized pockets of CO2 form, allowing crewmembers to be 
exposed to higher concentrations of CO2 than are recorded 
by the MCA
• Individual susceptibility of crewmembers
• Exposure to above-normal CO2 levels may sensitize some 
individuals to CO2 and build tolerance to higher than normal 
CO2 in others
• Symptoms develop when there are large or rapid excursions 
in CO2 from an established baseline
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Conclusion
• There is increasing awareness of CO2 symptoms by 
crew and ground teams
• There is mounting evidence that there are health and 
performance impacts at recent ISS CO2 levels
• An operational limit between 0.5 and 2.0 mmHg may maintain 
health and performance, but data are limited due to hardware
• 3.0 mmHg is more achievable in the short term – new 
operational limit since summer 2015
• May be below the threshold for frank headaches for many crewmembers 
but still likely to be associated with CO2 symptoms
• Future work is needed to establish long-term ISS and 
future vehicle operational limits
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